Review

Role of serum P1NP measurement for monitoring treatment response in osteoporosis

Michael Samoszuk

† Author for correspondence

Roche Diagnostics Corporation, 9115 Hague Road, PO Box 50457, Indianapolis, IN 46250-0457, USA.

Search for more papers by this author

Email the corresponding author at mike.samoszuk@roche.com

Michael Leuther

Roche Diagnostics Corporation, 9115 Hague Road, PO Box 50457, Indianapolis, IN 46250-0457, USA.

Search for more papers by this author

Email the corresponding author at mike.samoszuk@roche.com

Nicholas Hoyle

Roche Diagnostics Corporation, 9115 Hague Road, PO Box 50457, Indianapolis, IN 46250-0457, USA.

Search for more papers by this author

Email the corresponding author at mike.samoszuk@roche.com

Published Online:7 Nov 2008https://doi.org/10.2217/17520363.2.5.495

View article

Abstract

Osteoporosis is a generalized, essentially age related, skeletal disorder characterized by fragile bone. It is a major public health problem because of the high cumulative risk of bone fractures in affected populations. Although there is currently no cure for osteoporosis, there are effective treatments that can prevent additional bone loss by inhibiting the degradation of mature bone (antiresorptive therapy) or, ideally, reverse bone loss and thus increase bone density by stimulating the formation of new bone (anabolic therapy). Unfortunately, there is often poor adherence to and persistence with therapy in patients with osteoporosis because of the lack of timely positive reinforcement regarding the beneficial effects of treatment on bone density. Recently, however, substantial evidence has accumulated that a serum biomarker of bone formation, amino pro-peptide of type 1 collagen, can accurately identify those patients who are responding to anabolic or antiresorptive therapy within 3 months of the start of treatment. The use of this biomarker in patients being treated for osteoporosis may significantly improve therapy adherence and clinical outcomes.

Keywords:

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

1 Sambrook P, Cooper C: Osteoporosis. Lancet367,2010–2018 (2006).•• Provides an outstanding overview of the clinical and pathologic features of osteoporosis.Crossref, Medline, CAS, Google Scholar
2 Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. US Department of Health and Human Services, Office of the Surgeon General. Rockville, USA (2004).• Excellent summary of bone metabolism and the epidemiology of osteoporosis.Google Scholar
3 Styrkarsdottir U, Halldorsson B, Gretarsdottir S et al.: Multiple genetic loci for bone mineral density and fractures. N. Engl. J. Med.358,2355–2365 (2008).Crossref, Medline, CAS, Google Scholar
4 Vesper H, Cosman F, Endres D et al.: Application of biochemical markers of bone turnover in the assessment and monitoring of bone diseases; approved guideline. NCCLS24(22),1–8 (2004).•• Technical document provides a detailed and comprehensive description of the various biomarkers that are available for assessing bone turnover.Google Scholar
5 Martin TJ, Sims NA: Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med.11(2),76–81 (2005).Crossref, Medline, CAS, Google Scholar
6 Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature423,337–342 (2003).Crossref, Medline, CAS, Google Scholar
7 Huybrechts KF, Ishak KJ, Caro JJ: Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone38,922–928 (2006).Crossref, Medline, Google Scholar
8 Tosteson AN, Grove MR, Hammond CS et al.: Early discontinuation of treatment for osteoporosis. Am. J. Med.115(3),209–216 (2003).Crossref, Medline, Google Scholar
9 Delmas PD, Brijens B, Eastell R et al.: Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab.92(4),1296–1304 (2007).Crossref, Medline, CAS, Google Scholar
10 Clowes JA, Peel NFA, Eastell R: The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J. Clin. Endocrinol. Metab.89(3),1117–1123 (2004).Crossref, Medline, CAS, Google Scholar
11 Bonnick SL, Shulman L: Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am. J. Med.119(4A),25S–31S (2006).Crossref, Medline, Google Scholar
12 Compston JE, Seeman E: Compliance with osteoporosis therapy is the weakest link. Lancet368,973–947 (2006).Crossref, Medline, Google Scholar
13 Lekkerkerker F, Kanis JA, Alsayed N et al.: Adherence to treatment of osteoporosis: a need for study. Osteoporos. Int.18,1311–1317 (2007).Crossref, Medline, CAS, Google Scholar
14 Garnero P, Vergnaud P, Hoyle N: Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin. Chem.54(1),188–196 (2008).•• Presents detailed performance data for an automated assay for P1NP and also provides an excellent review of clinical and biological properties of this biomarker.Crossref, Medline, CAS, Google Scholar
15 Black DM, Greenspan SL, Ensrud KE et al.: The effects of PTH(1–84) and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med.349,1207–1215 (2003).•• Key paper describing the use of N-terminal propeptide of type 1 collagen (P1NP) to measure the clinical response to alendronate and parathyroid hormone (1–84).Crossref, Medline, CAS, Google Scholar
16 Reginster JY, Sarkar S, Zegels B et al.: Reduction in P1NP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone34,344–351 (2004).Crossref, Medline, CAS, Google Scholar
17 Sebba AI, Bonnick SL, Kagan R et al.: Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr. Med. Res. Opin.20,2031–2041 (2004).Crossref, Medline, CAS, Google Scholar
18 Rosen CJ, Hochberg MC, Bonnick SL et al.: Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res.20(1) 141–151 (2005).Crossref, Medline, CAS, Google Scholar
19 Tahtela R, Seppanen J, Laitinen K, Katajamaki A, Risteli J, Valimaki MJ: Serum tartrate-resistent acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propetide. Osteoporos. Int.16,1109–1116 (2005).Crossref, Medline, Google Scholar
20 Black DM, Bilezikian JP, Ensrud KE et al.: One year of alendronate after one year of PTH(1–84) for osteoporosis. N. Engl. J. Med.353(6),555–565 (2005).Crossref, Medline, CAS, Google Scholar
21 Chen P, Satterwhite JH, Licata AA et al.: Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res.20(6),962–970 (2005).Crossref, Medline, CAS, Google Scholar
22 Nenonen A, Cheng S, Ivaska KK et al.: Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J. Bone Miner. Res.20(8),1804–1812 (2005).Crossref, Medline, CAS, Google Scholar
23 Deal C, Omizo M, Schwartz EN et al.: Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results form a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res.20(11),1905–1911 (2005).Crossref, Medline, CAS, Google Scholar
24 McClung MR, San Martin J, Miller PD et al.: Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med.165,1762–1768 (2005).• Provides a detailed discussion of the opposite effects of bisphosphonates and anabolic therapy on bone turnover markers such as P1NP.Crossref, Medline, CAS, Google Scholar
25 Eastell R, Krege JH, Chen Peiqu, Glass EV, Reginster J-Y: Development of an algorithm for using P1NP to monitor treatment of patients with teriparatide. Curr. Med. Res. Opin.22(1),61–66 (2006).Crossref, Medline, CAS, Google Scholar
26 Krege JH, Blumsohn A, Nickelsen TA, Marin F, Chen P, Eastell R: Testing an algorithm for using P1NP to monitor treatment of patients with teriparatide. J. Bone Miner. Res.21(Suppl. 1),S302 (2006).Crossref, Google Scholar
27 Middleton ET, Steel SA, Doherty SM: The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice. Calcif. Tissue Int.81,335–340 (2007).Crossref, Medline, CAS, Google Scholar
28 Anastasilakis AD, Goulis DG, Polyzos SA et al.: Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomized trial. Int. J. Clin. Pract.1768,1–6 (2008).Google Scholar
29 Miller PD: Monitoring osteoporosis therapies. Curr. Osteoporos. Rep.5(1),38–43 (2007).•• Outstanding summary of the clinical value of monitoring osteoporosis therapy.Crossref, Medline, Google Scholar
30 Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY: Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab.90,1294–1301 (2005).Crossref, Medline, CAS, Google Scholar
31 Armamento-Villareal R, Panwar V, Novack D: Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N. Engl. J. Med.355(19),2048–2050 (2006).Crossref, Medline, CAS, Google Scholar
32 Schneider JP: Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics61,31–33 (2006).Medline, Google Scholar
33 Goh SK, Yang KY, Koh JS et al.: Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J. Bone Joint Surg. Br.89,349–353 (2007).Crossref, Medline, Google Scholar
34 Imai K, Yamamoto S, Anamizu Y, Horiuchi T: Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J. Bone Miner. Metab.25,333–336 (2007).Crossref, Medline, Google Scholar
35 Cheung RKH, Leung KK, Lee KC, Chow TC: Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med. J.13,485–489 (2007).Medline, Google Scholar
36 Lenart BA, Lorich DG, Lane JM: Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N. Engl. J. Med.358,1304–1306 (2008).Crossref, Medline, CAS, Google Scholar
37 Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG: Low-energy femoral shaft fractures associated with alendronate use. J. Orthop. Trauma.22(5),346–350 (2008).Crossref, Medline, Google Scholar
38 Kwek EBK, Goh SK, Koh JSB, Png MA, Howe TS: An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury Int. J. Care Injured39,224–231 (2008).Crossref, Medline, Google Scholar
39 Visekruna M, Wilson D, McKiernan FE: Severely suppressed bone turnover and atypical skeletal fragility. J. Clin. Endocrinol. Metab.93(8),2948–2952 (2008).Crossref, Medline, CAS, Google Scholar
101 Nucleus Inc. www.nucleusinc.comGoogle Scholar

Vol. 2, No. 5

Metrics

Downloaded 344 times

History

Published online 7 November 2008

Published in print October 2008

Information

Keywords

Acknowledgements

The authors thank B Schuster for her administrative assitance in preparing the manuscript.

Financial & competing interests disclosure

The authors are full-time employees of Roche Diagnostics Corporation which manufactures and distributes the Elecsys total P1NP test. M Samoszuk also holds settled stock appreciation rights in Roche. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download